Table 1.

Summary of included studies

Study, year; country	Trial acronym; study design	Study population	Treatment/control comparisons	COL dosage	FU period (mo.)	Sample size (treatment/control)
Jolly et al. [8], 2024; 14 countries	CLEAR; DB RCT	MI	COL/PL	0.5 mg BID for pts >70 kg and OD for <70 kg for 90 d; then, 0.5 mg OD for all	36	3528/3534
Kelly et al. [9], 2024; 13 European countries, Canada	CONVINCE; OL RCT	IS/TIA	COL/SC	0.5 mg OD	33.6	1569/1575
Li et al. [10], 2024; China	CHANCE-3; DB RCT	IS/TIA	COL/PL	0.5 mg BID for 3 d, then 0.5 mg OD	3	4176/4167
Khiali et al. [20], 2024; Iran	NA; DB RCT	STEMI	COL + EMP/EMP only	0.5 mg BID	3	35/36
Bouleti et al. [21], 2024; France	CONVERT-MI [22]; DB RCT	STEMI	COL/PL	2 mg LD, then 0.5 mg BID for 5 d	12	101/91
Akrami et al. [23], 2021; Iran	NA; DB RCT	ACS	COL/PL	0.5 mg OD	6	120/129
Nidorf et al. [24], 2020; Australia, Netherlands	LoDoCo2; DB RCT	CAD	COL/PL	0.5 mg OD	28.6	2762/2760
Tong et al. [25], 2020; Australia	COPS; DB RCT	ACS	COL/PL	0.5 mg BID for 1 mo, then 0.5 mg OD	12	396/399
Shah et al. [26], 2020; USA	COL-PCI; DB RCT	ACS/CAD	COL/PL	1.8 mg single dose before PCI	1	206/194
Hennessy et al. [27], 2019; Australia	LoDoCo-MI; DB RCT	MI	COL/PL	0.5 mg OD	1	111/113
Tardif et al. [28], 2019; 12 countries	COLCOT; DB RCT	MI	COL/PL	0.5 mg OD	22.6	2366/2379
Akodad et al. [29], 2017; France	COLIN; OL RCT	Acute STEMI underwent primary PCI	COL/SC	1 mg OD	1	23/21
Nidorf et al. [30], 2013; Australia	LoDoCo; OL RCT	CAD	COL/SC	0.5 mg OD	36	282/250
Raju et al. [31], 2012; Australia	COOL; DB RCT	ACS/IS	COL/PL	1 mg OD	1	36/38

ACS acute coronary syndrome, BID twice daily, CAD coronary artery disease, COL colchicine, d day(s), DB double blind, EMP empagliflozin, FU follow-up, IS ischemic stroke, LD loading dose, MI myocardial infarction, mo month, NA not applicable, OD once daily, OL open label, PCI percutaneous coronary intervention, PL placebo, PTS patients, RCT randomized controlled trial, SC standard care, STEMI ST-elevated MI, TIA transient ischemic attack